AMRX vs STE · P/E 44, rev $2.79B vs P/E 25, rev $5.46B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus STERIS plc (STE) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
STERIS plc (STE) is a medical devices company listed on NYSE.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported STE revenue for 2025-03-31 was $5.46B. Net income was $616.1M. Revenue was up 284.6% from 2024-03-31 to 2025-03-31. STE currently screens at market cap $19.43B and trailing P/E 25.1.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. STE currently screens at market cap $19.43B and trailing P/E 25.1.
Not investment advice. Open the AMRX and STE stock pages for the full models.
Not investment advice.